Streamlining Prior Authorization: Strategies for Securing Timely Access to New RRFL Regimens

In this episode, 'Streamlining Prior Authorization: Strategies for Securing Timely Access to New RRFL Regimens,' Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following question:

Prior authorization and payer coverage dynamics represent a significant operational challenge for new regimens in RRFL. How do you approach the prior authorization process for newer combination regimens, and what strategies have proven most effective in ensuring timely patient access?

Ryan Haumschild outlined a proactive, infrastructure-driven approach to prior authorization for newer RRFL combination regimens, emphasizing that the most common reason for denials is not an inappropriate therapy choice but rather incomplete or poorly documented submissions, making the upfront investment in comprehensive, diagnosis-specific order sets and thorough documentation packages the single most impactful strategy for improving first-pass approval rates. He also stressed the importance of ensuring that clinical information captured in the patient chart is accurately and completely translated into the prior authorization submission, as payers are generally willing to approve therapies used for the right population when the evidence is clearly presented. Ryan Haumschild further recommended that institutions proactively develop pre-built appeal letters and peer-to-peer templates for key regimens, including clear documentation of why patients meet clinical criteria, such as POD24 status or demonstrated inadequacy of R², so that when denials do occur, the response infrastructure is already in place to resolve them quickly and keep time to treatment as short as possible.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Living with Follicular Lymphoma: Counseling Patients, Evolving Treatments, and Remaining Unmet Needs,' Christina Poh, MD will share her perspective on follicular lymphoma as an academic oncologist, discussing how she frames the chronic, relapsing nature of the disease for her patients, how the treatment landscape has evolved with the emergence of bispecific antibodies, tafasitamab-based combinations, and CAR-T cell therapy, and what she considers the most significant unmet needs remaining in the relapsed or refractory setting today.